Combination Therapy of Extrapyramidal Disease with Trihexyphenidyl and L-Dopa

1979 ◽  
Vol 7 (1) ◽  
pp. 19-28 ◽  
Author(s):  
H Hökendorf
Keyword(s):  
Side Effects ◽  
Combination Therapy ◽  
Motor System ◽  
Good Control ◽  
Decarboxylase Inhibitor ◽  
System Disease ◽  
Extrapyramidal Disease ◽  
Extrapyramidal Motor

An electromyographic method was used to study the effect of combination therapy with L-dopa and trihexyphenidyl on tremor in thirty patients suffering from extrapyramidal motor system disease. In this method tremor activity was measured and documented so that the course of the disease could be followed objectively. L-dopa alone was slightly more effective against tremor than was trihexyphenidyl alone. The combination of the two drugs was more effective than either drug used alone, and its side-effects were mild and definitely fewer than had been reported with L-dopa combined with a decarboxylase inhibitor. Good control of tremor with L-dopa and trihexyphenidyl was obtained clinically and verified electromyographically.

Dopamine agonists for parkinson’s disease

1991 ◽  
Vol 29 (2) ◽  
pp. 7-8
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Side Effects ◽  
Therapeutic Efficacy ◽  
Dopamine Agonists ◽  
Dopa Decarboxylase ◽  
Decarboxylase Inhibitor ◽  
Duration Of Action ◽  
Motor Disability ◽  
The Uk

Bromocriptine, lysuride (formerly lisuride, Revanil – Roche) and pergolide (not yet marketed in the UK) are dopamine agonists developed for use in the treatment of patients with Parkinson’s disease. Combination of a dopamine agonist with levodopa plus a dopa-decarboxylase inhibitor (‘co-dieldopa’)* may have advantages at all stages of the disease. The aim of combined co-dieldopa + agonist treatment is to limit some of the problems with prolonged co-dieldopa use alone; especially fluctuations in motor disability.1 It is still not clear how the three agonists compare with each other for therapeutic efficacy, duration of action, and side effects, nor how they are best combined with co-dieldopa.

Tissue atrophy and elevated iron concentration in the extrapyramidal motor system in Friedreich ataxia: the IMAGE-FRDA study

2016 ◽  
Vol 87 (11) ◽  
pp. 1261-1263 ◽  
Author(s):  
Ian H Harding ◽  
Parnesh Raniga ◽  
Martin B Delatycki ◽  
Monique R Stagnitti ◽  
Louise A Corben ◽  
...  
Keyword(s):  
Motor System ◽  
Iron Concentration ◽  
Friedreich Ataxia ◽  
Extrapyramidal Motor

scholarly journals Combination Therapy with Continuous Three-in-One Femoral Nerve Block and Periarticular Multimodal Drug Infiltration after Total Hip Arthroplasty

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Tomonori Tetsunaga ◽  
Tomoko Tetsunaga ◽  
Kazuo Fujiwara ◽  
Hirosuke Endo ◽  
Toshifumi Ozaki
Keyword(s):  
Side Effects ◽  
Pain Relief ◽  
Total Hip Arthroplasty ◽  
Combination Therapy ◽  
Hospital Stay ◽  
Nerve Block ◽  
Hip Arthroplasty ◽  
Femoral Nerve Block ◽  
Femoral Nerve ◽  
Length Of Hospital Stay

Background. Various postoperative pain relief modalities, including continuous femoral nerve block (CFNB), local infiltration analgesia (LIA), and combination therapy, have been reported for total knee arthroplasty. However, no studies have compared CFNB with LIA for total hip arthroplasty (THA). The aim of this study was to compare the efficacy of CFNB versus LIA after THA. Methods. We retrospectively reviewed the postoperative outcomes of 93 THA patients (20 men, 73 women; mean age 69.2 years). Patients were divided into three groups according to postoperative analgesic technique: CFNB, LIA, or combined CFNB+LIA. We measured the following postoperative outcome parameters: visual analog scale (VAS) for pain at rest, supplemental analgesia, side effects, mobilization, length of hospital stay, and Harris Hip Score (HHS). Results. The CFNB+LIA group had significantly lower VAS pain scores than the CFNB and LIA groups on postoperative day 1. There were no significant differences among the three groups in use of supplemental analgesia, side effects, mobilization, length of hospital stay, or HHS at 3 months after THA. Conclusions. Although there were no clinically significant differences in outcomes among the three groups, combination therapy with CFNB and LIA provided better pain relief after THA than CFNB or LIA alone, with few side effects.

scholarly journals Opening the time window

2019 ◽  
Vol 39 (12) ◽  
pp. 2539-2540 ◽  
Author(s):  
Klaus van Leyen ◽  
Xiaoying Wang ◽  
Magdy Selim ◽  
Eng H Lo
Keyword(s):  
Side Effects ◽  
Combination Therapy ◽  
Patient Selection ◽  
Endovascular Therapy ◽  
Perfusion Imaging ◽  
Paradigm Shift ◽  
Time Window ◽  
Stroke Therapy ◽  
Image Guided ◽  
Tissue Plasminogen

The recently completed EXTEND trial tested the idea that tissue plasminogen activator thrombolysis can be safely extended up to 9 h after stroke onset if automated perfusion imaging indicates the presence of a salvageable penumbra. This important trial contributes to an ongoing paradigm shift for stroke therapy. Combined with the introduction of endovascular therapy, image-guided patient selection is expanding the toolbox of the stroke practitioner. At the same time, pushing the limits of reperfusion has raised important questions about mechanisms to pursue for combination therapy as well as potential approaches to mitigate side effects and optimize treatments for patients with various co-morbidities.

scholarly journals The Effect of Systemic Methotrexate and Cyclosporine Combination Therapy inPsoriasis Vulgaris Patients in Bandung, Indonesia

2021 ◽  
Vol 33 (3) ◽  
pp. 200
Author(s):  
Oki Suwarsa ◽  
Fatima Aulia Khairani ◽  
Syawalika Ulya Isneny ◽  
Erda Avriyanti ◽  
Hartati Purbo Dharmadji ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Side Effects ◽  
Adverse Effects ◽  
Combination Therapy ◽  
Combination Treatment ◽  
Psoriasis Vulgaris ◽  
Severity Index ◽  
Dermatology Clinic ◽  
Significant Difference ◽  
Pasi Score

Background: Methotrexate (MTX) and cyclosporine have been used as effective systemic mono-therapy for psoriasis. Several factors are considered to switch monotherapy to combination therapy because monotherapy is no longer effective and has higher side effects. Hence,clinicians have avoided systemic therapy combinations due to its toxicity. However, some studies showed that this combination therapy could be usedeffectively for psoriasis patients. Purpose: This study aimed to analyze the efficacy and adverse effects of systemic MTX and cyclosporine combination therapy in Indonesian psoriasis vulgaris patients. Methods: The retrospective study assessed the effectiveness of 3 monthsmono-therapyand combination therapy of systemic MTX and cyclosporine in psoriasisvulgaris patients from 2016–2017 in Dermatology Clinic, Dr. Hasan Sadikin Hospital, Bandung, West Java, Indonesia. Result: Psoriasis area and severity index (PASI) score 90 were achieved in the group MTX (50%) and cyclosporine group (50%), while none in the combination group.However, eight patients (50%) in group MTX and cyclosporine reached the primary endpoint of PASI 50. One patient in cyclosporine group had adverse effects on kidney profiles. Nonetheless, other patients had no biochemical changes. But, there was no significant difference in the change of PASI between each group (p=0.102). Conclusion: We propose that combination therapy of MTX and cyclosporine is relatively safe and efficacious in treating Indonesian psoriasis vulgaris patients. This combination treatment isas effective as MTX or cyclosporinemono-therapy.

Combination therapy with acipimox enhances the effect of growth hormone treatment on linear body growth in the normal and small-for-gestational-age rat

2006 ◽  
Vol 291 (6) ◽  
pp. E1212-E1219 ◽  
Author(s):  
M. H. Vickers ◽  
P. L. Hofman ◽  
P. D. Gluckman ◽  
P. E. Lobie ◽  
W. S. Cutfield
Keyword(s):  
Growth Hormone ◽  
Side Effects ◽  
Combination Therapy ◽  
Gestational Age ◽  
Combination Treatment ◽  
Small For Gestational Age ◽  
Body Growth ◽  
Maternal Undernutrition ◽  
Fasting Plasma ◽  
Linear Body

Growth hormone (GH) therapy is often associated with adverse side effects, including impaired insulin sensitivity. GH treatment of children with idiopathic short stature does not lead to an optimized final adult height. It has been demonstrated that FFA reduction induced by pharmacological antilipolysis can stimulate GH secretion per se in both normal subjects and those with GH deficiency. However, to date, no investigation has been undertaken to establish efficacy of combination treatment with GH and FFA regulators on linear body growth. Using a model of maternal undernutrition in the rat to induce growth-restricted offspring, we investigated the hypothesis that combination treatment with GH and FFA regulators can enhance linear body growth above that of GH alone. At postnatal day 28, male offspring of normally nourished mothers (controls) and offspring born with low birth weight [small for gestational age (SGA)] were treated with saline, GH, or GH (5 mg·kg−1·day−1) in combination with acipimox (GH + acipimox, 20 mg·kg−1·day−1) or fenofibrate (GH + fenofibrate, 30 mg·kg−1·day−1) for 40 days. GH plus acipimox treatment significantly enhanced linear body growth in the control and SGA animals above that of GH, as quantified by tibial and total body length. Treatment with GH significantly increased fasting plasma insulin, insulin-to-glucose ratio, and plasma volumes in control and SGA animals but was not significantly different between saline and GH-plus-acipimox-treated animals. GH-induced lipolysis was blocked by GH plus acipimox treatment in both control and SGA animals, concomitant with a significant reduction in fasting plasma FFA and insulin concentrations. This is the first study to show that GH plus acipimox combination therapy, via pharmacological blocking of lipolysis during GH exposure, can significantly enhance the efficacy of GH in linear growth promotion and ameliorate unwanted metabolic side effects.

Extrapyramidal Motor Side Effects

2010 ◽  
pp. 525-525
Author(s):  
Bart Ellenbroek ◽  
Alfonso Abizaid ◽  
Shimon Amir ◽  
Martina de Zwaan ◽  
Sarah Parylak ◽  
...  
Keyword(s):  
Side Effects ◽  
Extrapyramidal Motor

Infection in a pregnant patient on immunosuppressive treatment

2021 ◽  
pp. 95-108
Author(s):  
Maria Rhona G. Bergantin ◽  
Sandra V. Navarra
Keyword(s):  
Side Effects ◽  
Immunosuppressive Treatment ◽  
Clinical Manifestations ◽  
Good Control ◽  
Pregnant Patient ◽  
Immunosuppressive Drugs ◽  
Modes Of Transmission ◽  
Autoimmune Rheumatic Diseases ◽  
Pregnancy And Lactation ◽  
Special Challenge

Patients on immunosuppressive therapies have greater susceptibility to a broad range of infections and pose a special challenge during pregnancy and lactation. Anti-microbials must be given with due consideration to side-effects, drug-drug interactions, and importantly safety to the growing foetus and the breastfeeding baby. This chapter further elucidates on modes of transmission and prevention of some infections which can significantly impact materno-foetal outcomes. Systemic autoimmune diseases must be kept under good control during pregnancy since untreated disease carries its own risks to both the mother and the developing foetus. Whilst infections are an important complication of immunosuppressive drugs used for many autoimmune rheumatic diseases, their clinical manifestations may be masked or absent among immunosuppressed individuals.

scholarly journals THE ADDITIVITY ANTINOCICEPTIVE INTERACTIONS BETWEEN DICLOFENAC AND THE DERRIS SCANDENS EXTRACT DRUG IN MICE.

2018 ◽  
Vol 11 (1) ◽  
pp. 314
Author(s):  
Tadsanee Punjanon
Keyword(s):  
Acetic Acid ◽  
Side Effects ◽  
Combination Therapy ◽  
Dose Response ◽  
Pain Treatment ◽  
Fixed Ratio ◽  
Drug Dose ◽  
Response Curves ◽  
Interaction Index ◽  
Abdominal Constriction

 Objective: Combination therapy is a valid approach in pain treatment, in which a reduction of doses could reduce side effects and still achieve optimal analgesia. The objective was to determine the effects of coadministered diclofenac and the Derris scandens extract drug.Methods: Acetic acid-induced abdominal constriction test in mice was used to determine the type of interaction between components. The effective dose that produced 50% antinociception (ED50) was calculated from the log dose-response curves of fixed ratio combinations of diclofenac with the D. scandens extract drug. The ED50 was compared to the theoretical additive ED50 calculated from the ED50 of diclofenac and of the D. scandens extract drug alone.Results: Diclofenac and the D. scandens extract drug dose‐dependently and significantly reduced the abdominal writhing. The combination was the additive effect, the experimental ED50 being smaller than the theoretically calculated ED50. Interaction index of the combination was 0.89.Conclusion: The present study demonstrates the additivity antinociceptive interactions between diclofenac and the D. scandens extract drug and may be used as a combination analgesic in the treatment of pain conditions.

Sign in / Sign up

Export Citation Format

Share Document